CompletedNot applicableNCT02750501
Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alcresta Therapeutics, Inc.
- Principal Investigator
- Madhumalli Sarkar, MD, PhDAlcresta Therapeutics, Inc.
- Intervention
- RELiZORB (immobilized lipase) cartridge(device)
- Enrollment
- 49 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2016 – 2017
Study locations (10)
- Joe DiMaggio Children's Hospital / Memorial Healthcare System, Hollywood, Florida, United States
- St. Luke's CF Center of Idaho, Boise, Idaho, United States
- Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
- Maine Medical Center, Portland, Maine, United States
- Helen DeVos Children's Hospital CF Care Center, Grand Rapids, Michigan, United States
- Children's Mercy Hospital, Kansas City, Missouri, United States
- Cardinal Glennon Children's Hospital / Saint Louis University, St Louis, Missouri, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Dayton Children's Hospital, Dayton, Ohio, United States
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Collaborators
Cystic Fibrosis Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02750501 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.